1 Forty-three subjects in remission from a major depressive episode who underwent TRP depletion were genotyped. DNA was extracted from blood lymphocytes or from cheek cells.
Although the TRP-free amino acid drink utilized in this project rapidly and consistently depletes plasma levels of this 5-HT precursor, 4 ,5 reduces 5-HT synthesis, 6, 7 and lowers cerebrospinal fluid levels of the 5-HT metabolite 5HIAA, 8, 9 the behavioral responses observed in subjects with similar clinical and treatment history vary dramatically. Delgado et al 10 reported that individuals recently achieving remission from major depression during treatment with a serotonin reuptake inhibitor experienced a transient return of depressive symptoms, but not all subjects experienced a similarly dramatic response. Others have replicated these findings, also noticing differing rates of mood response. 11, 12 Benkelfat et al 13 and Klaassen et al 14 showed that healthy subjects with a family history of affective disorders were more likely than healthy controls to experience mood changes in response to TRP depletion. Although the effect for group was statistically significant, the degree of mood response within each group was also varied. Smith et al 15 and Moreno et al 5 reported that medication-free remitted depressed patients also experience transient depressive changes in response to TRP depletion. In these studies, the response was also varied with about two thirds of the subjects accounting for most of the mood changes observed. Furthermore, Leyton et al, 16 while studying a similar population, reported that only a small portion of their subjects experienced mood response during TRP depletion. An important and unanswered question remains: What determines which subjects will experience a mood response to TRP depletion and which ones will not?
A number of potential explanations have been proposed including the possibility that individuals having depressive mood responses to TRP depletion are doing so because their brain 5-HT has depleted more than for those with no mood response. A variable that may affect the degree of 5-HT availability in the synaptic cleft and neurotransmission is the degree of expression of the 5-HT transporter protein (SERT), which plays a role in uptake of 5-HT into the presynaptic cell by a sodium-dependent mechanism. In vitro studies have demonstrated that the l allele of the polymorphism targeted in this study is associated with a two to three times higher basal transcriptional activity, and higher activity in response to cyclic AMP and protein kinase C, than the s allele. 17 Similarly, Lesch et al 1 found greater levels of SERT m-RNA in ll cells, than ls cells, or ss, and uptake of labeled 5-HT in ll cells was 1.9-2.2 times the amount in ls or ss cells. These studies suggest that the s allele has a dominant effect.
Based on this information, we hypothesize that when the rapid uptake of 5-HT in ll subjects is combined with decreased brain 5-HT availability during TRP depletion, a greater decrease in 5-HT neurotransmission might occur, resulting in a greater clinical depressive response to this test. This may explain the study findings, and further suggests that genetic variability may help determine who will experience mood response during TRP depletion.
Supporting the notion that behavioral syndromes are influenced by polymorphic SLC6A4 variation, McDougle et al 18 demonstrated evidence for linkage disequilibrium between the l allele and obsessive compulsive disorder (OCD). Du et al 19 reported a significantly higher frequency of the l allele in depressive-suicide victims compared to control subjects. Inconsistent with this finding, Ohara et al 20 failed to find any association between alleles of SLC6A4 and mood disorders in Japanese patients, however, there are highly significant differences in SLC6A4 allele frequency between Europeans and Japanese populations. 21 Mann et al 22 described a stronger association between ls and major depression history in a postmortem sample. We hypothesized that SLC6A4 genotype would moderate the response to TRP depletion. Subjects took the amino acid drink test in the morning and were rated for depression at baseline, 5, 7, and 26 h after ingestion of the drink. For the group as a whole, TRP depletion induced significant depressive symptoms as demonstrated by the increase (between baseline and peak) in HDRS of 6.58 ± 8.04 (Mean ± SD), with a main effect of time (F = 5.422, df = 3, 39, P = 0.003) in ANOVA with repeated measures for all the time points recorded. Repeated measures ANOVA allowed for a test of interaction of genotype with time for each of the three observed genotypes (ll (n = 13), ls (n = 14), and ss (n = 16)). There was an association between the ll genotype and the depressive response to TRP depletion, with a significant main effect of time (F = 8.763, df = 3, 38, P = Ͻ0.001), and a time × ll genotype interaction (F = 3.676, df = 3, 38, P = 0.02). Mean ± SD HDRS score increase for subjects with the ll genotype was 11.0 ± 9.75. Subjects with the ls genotype had no association with the changes in depressive symptoms, having a main effect of time (F = 4.307, df = 3, 38, P = 0.01), and time × ls genotype interaction (F = 0.679, df = 3, 38, P = 0.570). Mean ± SD HDRS score increase for subjects with the ls genotype was 5.5 ± 7.96. Similarly, the ss genotype was not significantly associated with the changes in depressive symptoms, having a main effect of time (F = 4.289, df = 3, 38, P = 0.011), and time × ss genotype interaction (F = 1.723, df = 3, 38, P = 0.179). Mean ± SD HDRS score increase for subjects with the ss genotype was 3.35 ± 4.43 (see Figure 1) .
Because of the ethnic variability for allele frequencies, 21 additional testing was conducted selecting only subjects of European descent (n = 37). In this subgroup, the genotype distribution was ll: n = 11, ls: n = 13, ss: n = 13. The depressive response was very similar with Mean ± SD HDRS score increase of 10.8 ± 9.88 for subjects with the ll, 5.92 ± 8.12 for subjects with the ls, and 4.3 ± 5.42 for subjects with the ss genotype. There was an association between the ll genotype and the depressive response to TRP depletion, with a significant main effect of time (F = 6.828, df = 3, 32, P = Ͻ0.001), and a trend for time × ll genotype interaction (F = 2.644, df = 3, 32, P = 0.066). The genotype frequencies in this sub-sample were ll = 0.030, ls = 0.35, and ss = 0.35, yielding allele frequencies of l = 0.475 and s = 0.525. The genotype frequencies did not depart It is important to consider that several environmental events may have an effect on the mood response to TRP depletion. These include the use of pharmacological agents immediately preceding depletion, the type of medication utilized, the presence of clinically severe depressive symptoms prior to depletion, the subject's sex, the season of the year, the phase of menstrual cycle, and the length of remission while on medication. Subjects participating in this study represent a highly heterogeneous population in terms of their age, sex, treatment history, severity and longevity of their depressive syndrome, etc. Although the frequency distribution of SLC6A4 alleles is also influenced by variables such as ethnicity, 21 the sample size in this study does not allow for independent testing of these variables and represents a limitation to the interpretation of the proposed findings.
There have been several clinical observations that support the notion that SLC6A4 variability may help to explain depression-related clinical events. Smeraldi et al, 23 and Zanardi et al 24 reported that individuals with the ll genotype have better antidepressant response to serotonin reuptake inhibitors than those with the ss variant. Similarly, Benedetti et al 25 reported
that ll subjects demonstrate a greater antidepressant response to total sleep deprivation than subjects with the ls or ss genotype. An important argument against the value of ll as a depression marker is the consistently reported decrease in SERT binding sites in postmortem brains of depressed patients. 22, 26 To further confound this issue, Mann et al 22 failed to find a correlation between SLC6A4 variation and SERT binding. Although these inconsistencies cannot be explained with the present data, it is possible that SERT expression may be influenced by environmental factors (ie pharmacological agents) or molecular events related to SERT's synthesis or feedback regulation among others.
These and other methodological limitations, such as the lack of a control population or a control test, mean there is clear need for replication of these findings in a larger, better characterized sample. However, these findings remain highly suggestive and may contribute to our understanding of the pathophysiology of depressive disorders, and the potential identification of subjects at risk for depressive episodes, or relapse after treatment.
For years, researchers have looked at a variety of distinctive clinical features and laboratory findings that have been proposed as potential predictors of MDEs, but their clinical application has been limited. Depressive response to TRP depletion has been recently proposed as a predictor of MDEs, 27 and seasonal affective disorder relapse. 28 Depression is a highly heterogeneous condition, with complex biological pathophysiology, influenced by genetic and environmental factors that may predispose, trigger, and maintain symptoms. Therefore, the predictive value of SLC6A4 might not be sufficient to be clinically applicable.
Genetic markers have the potential to more accurately identify individuals with biological vulnerability for a specific phenotype. Despite current advances in characterization and nosology, major depression remains a syndromal construct for which a genetic approach remains very complex and problematic. Because of limitations in phenotypic definitions that represent a rate limiting step in the identification of susceptibility genes, psychiatric geneticists have proposed an evolution from traditional syndromal diagnosis to the study of discrete entities such as consistent clinical or laboratory findings that would be more supportive of an etiological approach to classifications. 29, 30 The use of trait markers such as TRP depletion in combination with genetic approaches may help identify genetic markers by reducing the heterogeneity of the condition, ultimately facilitating our understanding, prediction and treatment of an important subgroup of depressives.
Methods
Forty-three (32 female, 11 male) subjects aged 25-72 years (45.4 ± 10.88), who participated in a variety of TRP depletion studies approved by the University of
Molecular Psychiatry
Arizona Human Subjects Committee and for which written informed consent had been obtained, agreed to be genotyped. All subjects were outpatients currently in remission from at least one prior Unipolar MDE according to DSM-III-R based on SCID interviews. Twelve of them were treatment-free for at least 3 months, 19 were receiving selective serotonin reuptake inhibitors (SSRIs), three were receiving non-SSRIs, and nine were receiving cognitive behavioral psychotherapy treatment. They were free of comorbid AXIS-I diagnosis or significant medical conditions that would compromise their safety during the study.
TRP depletion was accomplished by ingestion of a 102-g, TRP-free, 15-amino acid drink as described in prior studies. 4, 5 Behavioral ratings (HDRS and SC) were obtained in the morning 15 min prior to 5, 7, and 26 h after ingestion of the drink.
DNA was extracted directly from blood lymphocytes or from cheek cells collected in 4% sucrose using a modified diatom-binding procedure. 2 The target sequence was in the promoter region of the serotonin transporter gene.
1 PCR amplification of a 484-or 528-bp fragment was obtained using oligonucleotide primers to the nucleotide positions from −1416 to −1397 (stpr5, 5Ј GGCGTTGCCGCTCTGAATGC 3Ј) and from −910 to −888 (stpr3, 5Ј GAGGGACTGAGCTGGACAAC-CAC 3Ј). The 'long' allele containing a 44-bp insert was designated l. The 'short' allele without the insert was designated s. Amplification of this region was carried out in a reaction volume of 30 l made up of 30 ng genomic DNA, 0.26 mM dITP/dNTPs, 0.6 M sense and antisense primers, 10 mM KCl, 10 mM (NH 4 ) 2 SO 4 , 20 mM TrisFHCl (pH 8.8), 2 mM MgSO 4 , 0.1% Triton X-100, and 5 U Taq DNA polymerase. PCR amplification was performed in an MJ 100 Research Thermocycler located in the laboratory of Molecular and Systematic Evolution of the University of Arizona. After an initial hot start of 95°C for 30 s, the PCR program was 30 cycles of the following: 95°C for 30 s, 64°C for 30 s, and a smaller two-step loop alternating between 62°C for 30 s and 64°C for 30 s, a total of five times. A final extension was 68°C for 3 min.
